TrialBlood2013

Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase.

Andreas Hochhaus et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.